{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:04:55Z","timestamp":1792001095447,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s00262-020-02712-7","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T13:02:56Z","timestamp":1599138176000},"page":"679-687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Increased thyroid uptake on 18F-FDG PET\/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies"],"prefix":"10.1007","volume":"70","author":[{"given":"Alexandra","family":"Frelau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Palard-Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Jali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Boussemart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pandora","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Devillers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Le Jeune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lesimple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9472-9980","authenticated-orcid":false,"given":"Antoine","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"2712_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334","journal-title":"N Engl J Med"},{"key":"2712_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320\u2013330","journal-title":"N Engl J Med"},{"key":"2712_CR3","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521\u20132532","journal-title":"N Engl J Med"},{"key":"2712_CR4","doi-asserted-by":"crossref","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M et al. (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2712_CR5","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1210\/jc.2016-2300","volume":"101","author":"J De Filette","year":"2016","unstructured":"De Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B et al (2016) Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 101:4431\u20134439","journal-title":"J Clin Endocrinol Metab"},{"key":"2712_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28:583\u2013589","journal-title":"Ann Oncol"},{"key":"2712_CR7","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/cen.13297","volume":"86","author":"DL Morganstein","year":"2017","unstructured":"Morganstein DL, Lai Z, Spain L, Diem S, Levine D, Mace C et al (2017) Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 86:614\u2013620","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2712_CR8","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1001\/jama.2018.13995","volume":"320","author":"DB Johnson","year":"2018","unstructured":"Johnson DB, Chandra S, Sosman JA (2018) Immune checkpoint inhibitor toxicity in 2018. JAMA 320:1702\u20131703","journal-title":"JAMA"},{"key":"2712_CR9","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1089\/thy.2018.0116","volume":"28","author":"PC Iyer","year":"2018","unstructured":"Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR et al (2018) Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid 28:1243\u20131251","journal-title":"Thyroid"},{"key":"2712_CR10","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","volume":"5","author":"H Lee","year":"2017","unstructured":"Lee H, Hodi FS, Giobbie-Hurder A, Ott PA, Buchbinder EI, Haq R et al (2017) Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy. Cancer Immunol Res 5:1133\u20131140","journal-title":"Cancer Immunol Res"},{"key":"2712_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00259-019-04553-8","volume":"47","author":"P-Y Sala\u00fcn","year":"2020","unstructured":"Sala\u00fcn P-Y, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M et al (2020) Good clinical practice recommendations for the use of PET\/CT in oncology. Eur J Nucl Med Mol Imaging 47:28\u201350","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2712_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.acra.2016.08.005","volume":"24","author":"JW Wachsmann","year":"2017","unstructured":"Wachsmann JW, Ganti R, Peng F (2017) Immune-mediated disease in ipilimumab immunotherapy of melanoma with FDG PET-CT. Acad Radiol 24:111\u2013115","journal-title":"Acad Radiol"},{"key":"2712_CR13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2967\/jnmt.117.204933","volume":"46","author":"N Eshghi","year":"2018","unstructured":"Eshghi N, Garland LL, Nia E, Betancourt R, Krupinski E, Kuo PH (2018) 18F-FDG PET\/CT can predict development of thyroiditis due to immunotherapy for lung cancer. J Nucl Med Technol 46:260\u2013264","journal-title":"J Nucl Med Technol"},{"key":"2712_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","volume":"96","author":"A Mekki","year":"2018","unstructured":"Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot J-M, Lambotte O et al (2018) Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer 96:91\u2013104","journal-title":"Eur J Cancer"},{"key":"2712_CR15","doi-asserted-by":"publisher","first-page":"W992","DOI":"10.2214\/AJR.10.6198","volume":"197","author":"Y Bronstein","year":"2011","unstructured":"Bronstein Y, Ng CS, Hwu P, Hwu W-J (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti\u2013CTLA-4 antibody therapy. Am J Roentgenol 197:W992\u20131000","journal-title":"Am J Roentgenol"},{"key":"2712_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/CMR.0000000000000541","volume":"29","author":"C Sachpekidis","year":"2019","unstructured":"Sachpekidis C, Kopp-Schneider A, Hakim-Meibodi L, Dimitrakopoulou-Strauss A, Hassel JC (2019) 18F-FDG PET\/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Res 29:178\u2013186","journal-title":"Melanoma Res"},{"key":"2712_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00262-018-2279-9","volume":"68","author":"C Sachpekidis","year":"2019","unstructured":"Sachpekidis C, Larrib\u00e8re L, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A (2019) Can benign lymphoid tissue changes in 18F-FDG PET\/CT predict response to immunotherapy in metastatic melanoma? Cancer Immunol Immunother 68:297\u2013303","journal-title":"Cancer Immunol Immunother"},{"key":"2712_CR18","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1097\/RLU.0000000000002453","volume":"44","author":"T Nobashi","year":"2019","unstructured":"Nobashi T, Baratto L, Reddy SA, Srinivas S, Toriihara A, Hatami N et al (2019) Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET\/CT. Clin Nucl Med 44:e272\u2013e279","journal-title":"Clin Nucl Med"},{"key":"2712_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2019.0250","volume":"30","author":"A Kotwal","year":"2020","unstructured":"Kotwal A, Kottschade L, Ryder M (2020) PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid 30:177\u2013184","journal-title":"Thyroid"},{"key":"2712_CR20","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","volume":"45","author":"H Anwar","year":"2018","unstructured":"Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC et al (2018) Absolute number of new lesions on 18F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging 45:376\u2013383","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2712_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ando.2018.07.007","volume":"79","author":"F Illouz","year":"2028","unstructured":"Illouz F, Drui D, Caron P, Do CC (2028) Expert opinion on thyroid complications in immunotherapy. Ann Endocrinol 79:555\u2013561","journal-title":"Ann Endocrinol"},{"key":"2712_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.11613\/BM.2016.034","volume":"26","author":"F Habibzadeh","year":"2016","unstructured":"Habibzadeh F, Habibzadeh P, Yadollahie M (2016) On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochem Medica 26:297\u2013307","journal-title":"Biochem Medica"},{"issue":"96","key":"2712_CR23","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1651-2227.2006.00178.x","volume":"1992","author":"AK Akobeng","year":"2007","unstructured":"Akobeng AK (2007) Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr Oslo Nor 1992(96):644\u2013647","journal-title":"Acta Paediatr Oslo Nor"},{"key":"2712_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0167-9473(02)00225-6","volume":"43","author":"T Hothorn","year":"2003","unstructured":"Hothorn T, Lausen B (2003) On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal 43:121\u2013137 (MR1985332)","journal-title":"Comput Stat Data Anal"},{"key":"2712_CR25","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1210\/jc.2017-00448","volume":"102","author":"DA Delivanis","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S et al (2017) Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab 102:2770\u20132780","journal-title":"J Clin Endocrinol Metab"},{"key":"2712_CR26","doi-asserted-by":"publisher","first-page":"e0216954","DOI":"10.1371\/journal.pone.0216954","volume":"14","author":"I Yamauchi","year":"2019","unstructured":"Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M et al (2019) Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS ONE 14:e0216954","journal-title":"PLoS ONE"},{"key":"2712_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13044-018-0058-5","volume":"11","author":"N Edo","year":"2018","unstructured":"Edo N, Morita K, Sakamoto M, Kaminaga T, Edo H, Okamura E et al (2018) Correlation between anti-thyroid peroxidase antibody levels and diffuse thyroid uptake of 18F-fluorodeoxyglucose in Hashimoto\u2019s thyroiditis: a retrospective study. Thyroid Res 11:14","journal-title":"Thyroid Res"},{"key":"2712_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/s-0042-119528","volume":"125","author":"M Alhusseini","year":"2017","unstructured":"Alhusseini M, Samantray J (2017) Hypothyroidism in Cancer Patients on Immune Checkpoint Inhibitors with anti-PD1 Agents: Insights on Underlying Mechanisms. Exp Clin Endocrinol Diabetes 125:267\u2013269","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2712_CR29","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","volume":"13","author":"SG Downey","year":"2007","unstructured":"Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681\u20136688","journal-title":"Clin Cancer Res"},{"key":"2712_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R et al (2018) Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer. JAMA Oncol 4:374\u2013378","journal-title":"JAMA Oncol"},{"key":"2712_CR31","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"H-E Teulings","year":"2015","unstructured":"Teulings H-E, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33:773\u2013781","journal-title":"J Clin Oncol"},{"key":"2712_CR32","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","volume":"151","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA et al (2015) Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151:1206\u20131212","journal-title":"JAMA Dermatol"},{"key":"2712_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152:45\u201351","journal-title":"JAMA Dermatol"},{"key":"2712_CR34","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang T-O, Momtaz P, Postow MA, Callahan MK et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 33:3193\u20133198","journal-title":"J Clin Oncol"},{"key":"2712_CR35","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2217\/imt-2018-0146","volume":"11","author":"N Lang","year":"2019","unstructured":"Lang N, Dick J, Slynko A, Schulz C, Dimitrakopoulou-Strauss A, Sachpekidis C et al (2019) Clinical significance of signs of autoimmune colitis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy 11:667\u2013676","journal-title":"Immunotherapy"},{"key":"2712_CR36","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J et al (2017) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35:785\u2013792","journal-title":"J Clin Oncol"},{"key":"2712_CR37","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22:886\u2013894","journal-title":"Clin Cancer Res"},{"key":"2712_CR38","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s12020-019-01871-7","volume":"64","author":"I Peir\u00f3","year":"2019","unstructured":"Peir\u00f3 I, Palmero R, Iglesias P, D\u00edez JJ, Sim\u00f3-Servat A, Mar\u00edn JA et al (2019) Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. Endocrine 64:605\u2013613","journal-title":"Endocrine"},{"key":"2712_CR39","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1089\/thy.2019.0726","volume":"30","author":"EA Basak","year":"2020","unstructured":"Basak EA, van der Meer JWM, Hurkmans DP, Schreurs MWJ, Oomen-de Hoop E, van der Veldt AAM et al (2020) Overt thyroid dysfunction and anti- thyroid antibodies predict response to anti-PD-1 immunotherapy in cancer patients. Thyroid 30:966\u2013973","journal-title":"Thyroid"},{"key":"2712_CR40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","volume":"46","author":"N Aide","year":"2019","unstructured":"Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E (2019) FDG PET\/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging 46:238\u2013250","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2712_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4158\/EP-2019-0244","volume":"26","author":"M Al Mushref","year":"2019","unstructured":"Al Mushref M, Guido PA, Collichio FA, Moore DT, Clemmons DR (2019) Thyroid dysfunction, recovery, and prognosis in melanoma patients treated with immune checkpoint inhibitors: a retrospective review. Endocr Pract 26:36\u201342","journal-title":"Endocr Pract"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02712-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02712-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02712-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T22:13:42Z","timestamp":1630707222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02712-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["2712"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02712-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"22 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Because of the retrospective nature of this study, consent was not obtained. A simplified declaration to the French data protection authority (CNIL) under the number 208821 was performed for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}